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Abstract: Herein we describe the coating of polypeptidic micelles with sodium alginate as a 
strategy to improve the stability of micelles for drug delivery. Bedaquiline, approved in 2012 
for the treatment of multidrug resistant tuberculosis, has been used as example of hydrophobic 
drug for the study of the loading efficiency, of the release of the encapsulated drug in different 
media and of the in vitro antimicrobial activity of the system. Alginate coating prevented the 
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burst release of the drug from micelles upon dilution and led to a sustained release in all tested 
media. In view of possible oral administration, the alginate coated micelles showed better 
stability in gastric and intestinal simulated media. Notably, the encapsulated bedaquiline 
showed increased in vitro activity against M. tuberculosis compared to free bedaquiline.  
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1. Introduction 
Drugs used for the treatment of life threatening pathologies such as cancer or some infectious 
diseases often also carry serious undesired side effects. Moreover, the search of new active 
drugs is resulting quite difficult and efforts are being focused on the development of improved 
formulations of already known drugs.[1] 
Nanotechnology can provide diverse nanocarriers to reduce the side effects by decreasing the 
dose to be administered primarily through enhancing drug solubility, preventing its 
degradation, and consequently extending its circulation time.[2] 
Nanocarriers can be built from inorganic components, lipids, dendrimers and biodegradable 
polymers. Among them, polymers based on synthetic polypeptides have gained importance 
due to their biocompatibility, biodegradability and great chemical diversity of side chains 
which make them suitable for a broad variety of chemical modifications[3] including 
crosslinking groups,[4] stimuli responsive units,[5,6] and conjugation with drugs[7] or with 
active targeting species.[8,9] Using those strategies, synthetic polypeptides can be used as 
active therapeutic polymers but also as drug carriers in the form of hydrogels, vesicles, 
micelles or as components of polymeric nanoparticles.[8] Among them, micelles based on 
amphiphilic synthetic polypeptides have been reported for the encapsulation and delivery 
mainly of antitumoral drugs with hydrophobic nature taking advantage of their nanoscopic 
size suitable for the passive accumulation in tumors.[8] However, due to their supramolecular 
nature, micelles are prone to disassemble upon dilution or upon changes in the medium 
conditions, such as pH, or ionic strength.[10] The consequence is the burst release of the drug 
upon administration and the loss of the advantages of using a carrier. Thus, different strategies 
have been used for the stabilization of micelles such as covalent crosslinking [8,11] metal 
coordination[12] or ionic interactions.[13] However, the approach of stabilizing the micelles 
with a polymer coating remains unexplored. This strategy offers the opportunity for 
    
 - 4 - 
modularity, where a variety of polymers can be tested and used to obtain different properties 
for the surface of the carrier while preserving the encapsulation properties of the polymeric 
micelle. Polysaccharides derived from natural sources possess a great potential for this 
purpose since they are biocompatible, biodegradable and mucoadhesive.[14] They can form 
hydrogels and provide different functionalization depending on the natural source, i.e. amines, 
carboxylic acids. In particular, alginate is an FDA-approved polysaccharide that presents good 
mucoadhesive properties and undergoes gelation through coordination with metal ions, 
typically Ca2+.[15] Those metal ions are also susceptible of interaction with polyglutamate or 
polyaspartate segments in the hydrophilic block of an amphiphilic polypeptide. 
In the work presented here we aimed at demonstrating how alginate can be used as coating to 
stabilize polypeptidic micelles and how it can remarkably decrease the release of a 
hydrophobic drug encapsulated within their hydrophobic core. As hydrophobic block we have 
chosen poly(benzyloxycarbonyl lysine) for its good encapsulation properties of hydrophobic 
drugs.[16] Bedaquiline (BQ) was selected as lipophilic drug based on its importance regarding 
the treatment of multidrug-resistant (MDR) tuberculosis (TB). MDR-TB is a worldwide 
health problem recognized by the World Health Organization (WHO) since only 54 % of 
MDR-TB cases are currently being successfully treated worldwide.[17,18] In this context, BQ 
was granted approval by U.S. Food and Drug Administration (FDA) in 2012 to be used to 
treat MDR-TB in a multidrug treatment regime and when other options to treat this condition 
using other existing drugs have been exhausted. Albeit, it is a very effective drug, BQ has 
been associated to serious side effects including induction of life-threatening cardiac 
arrhythmias.[19] The aim of a nanotechnological approach in this case is to develop a 
nanocarrier for antimicrobial drug delivery that could help its safer administration and could 
be applied to treat other multidrug resistant infections in the future.[20] 
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2. Experimental Section 
2.1. General Methods 
γ-benzyl-L-glutamic acid (H-BnE-OH), ϵ-N-benzyloxycarbonyl-L-lysine (H-ZK-OH) and 
triphosgene were purchased from Fluorochem and used as received. Bedaquiline, nile red and 
sodium alginate (120.000-190.000 g mol-1) were obtained from Sigma-Aldrich and used as 
received. DMSO, DMF and THF were purchased from Acros Organic dried over 4 Å 
molecular sieves. Diethyl ether stabilized with BHT and hexane were purchased from 
Scharlab and used as received. BnE-NCA and ZK-NCA were prepared and recrystallized five 
times following published procedures as reported in the supplementary information.[21] 
Human plasma was purchased from Sigma-Aldrich. 
Dyalisis was performed in SnakeSkin™ dialysis tubing, with 3500 Da MWCO from 
ThermoFisher. Millex syringe driven filter unit (nylon) with a pore size of 0.45 μm were 
purchased from Merck Millipore. 
Difco™ Middlebrook 7H9 broth was purchased from BD and supplemented with 10% ADC 
and 0.05% Tween® 80 (Scharlau). Resazurin sodium salt was purchased from Sigma. 
2.2. Instruments and Measurements 
1H and 13C NMR spectra were recorded on a Bruker AV-400 spectrometer. Chemical shifts 
are given in ppm relative to the solvent residual peak, which was used as internal reference. 
Coupling constants are given in Hertz. Spectra were processed with MestReNova 10.0.2 
software from MestreLab Research. FTIR spectroscopy was performed in a Jasco FT-IR 4100 
instrument with an ATR accessory in which samples were measured without any preparation. 
All frequencies of characteristic bands were reported in cm-1. Syringe pump additions were 
performed with a New Era NE-300 Just Infusion equipment, employing HSW syringes. 
Polypeptides were characterized by combining a Waters 2695 GPC with a tandem of 
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detectors: multiangle laser light scattering (MALLS) detector at 60 °C, viscosimeter (DV) and 
refractive index (RI) from Wyatt Tech. The system was equipped with one guard and two 
columns Phenogel Linear (2) (5 m, 7.8 x 300 mm) from Phenomenex. HPLC-grade N,N-
dimethylacetamide (DMAc), containing 0.1 M LiBr, was used as the mobile phase at a flow 
rate of 1.0 mL min-1 and 60 °C. Concentrations between 1.0 and 5.0 mg mL-1 were injected 
into the columns at an injection volume of 200 μL. ASTRA software from Wyatt Technology 
was used to collect and analyze the data. Dynamic Light Scattering (DLS) analysis were 
carried out to obtain hydrodynamic diameter and polydispersity index (PDI) using a 
Brookhaven 90Plus DLS instrument, by means of the Photo-Correlation (PCS) technique. All 
measurements were done in Milli Q water at the concentration of 0.5 mg mL-1 for micelles 
and alginate-coated particles at 25 °C. Surface potential (ζ-potential) of each nanocarrier was 
determined by measuring the electrophoretic mobility of a 0.01 mg mL-1 nanocarrier 
suspension in aqueous 1 mM KCl at 25 °C with a Plus Particle Size Analyzer (Brookhaven 
Instruments Corporation). UV-Vis spectra were measured with a Varian Cary 50 UV/Vis 
spectrophotometer. 
2.3. Typical Polymerization Procedure 
ZK30-b-BnEn block co-polypeptides were prepared by successive monomer addition without 
intermediate purification steps using the method described by Zou et al. with minor 
modifications.[22] Different molecular weights and block ratios were obtained by varying the 
monomer to initiator ratio. In a typical polymerization procedure, ZK NCA (232 mg, 0.76 
mmol) was dried under high vacuum and transferred to a flame-dried Schlenk flask under N2 
atmosphere where dry DMF (0.5 mL) was also added. Next, a stock solution of butyl amine in 
dry DMF (0.5 % v/v) (0.5 mL) was added to the monomer solution under steady N2 flow with 
the N2 outlet connected to a drying agent (MgSO4). The reaction was monitored by FTIR-
ATR until NCA bands at 1850, 1789 and 920 cm-1 disappeared (about 3 h). Then a solution of 
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BnE NCA (200 mg, 0.76 mmol) in 1 mL of dry DMF was transferred via cannula to the 
Schlenk reaction flask. The reaction was further stirred under continuous N2 flow for 4 hours 
and then cooled down to 0 °C until total consumption of the monomer by FTIR-ATR. Once 
no monomer was detected in solution, the reaction mixture was poured into 40 mL of cold 
diethyl ether and centrifuged (4000 rpm, 10 min) to afford a white residue which was 
resuspended in fresh diethyl ether under sonication and centrifuged again. Finally, the residue 
obtained was dried under vacuum to afford the block copolymer as a white solid, in 
quantitative yield. 
2.4. Deprotection of the poly(benzyl glutamate) block[16] 
Benzyl protected block copolymer ZK30-b-BnEm (84 mg, 0.006 mmol) was dissolved in THF 
(8 mL) thereupon KOH (46 mg, 0.26 mmol) was added dissolved in the minimum amount of 
deionized water (50 μL). The reaction mixture was stirred overnight. The crude was poured 
into 20-fold excess of cold diethyl ether and cooled down to -23 °C for 1 h to allow full 
precipitation of the reaction product. Then, the sample was centrifuged (15 min, 4500 rpm) 
and the residue was dried under vacuum to afford a white solid which was further purified by 
dialysis (3500 MWCO) against water over 3 days. Finally, the deprotected block copolymer 
ZK30-b-Em was isolated as a white solid after freeze-drying.  
2.5. Preparation of empty micelles 
5 mg of the amphiphilic block copolypeptide were dissolved in DMSO (1 mL) and then 4 mL 
of a phosphate buffer solution (10 mM, pH 7.4) were added dropwise using a syringe pump 
with an addition rate of 0.1 mL min-1. The mixture was further stirred for 2 hours and then 
dialyzed against water by replacing it with fresh water 5 times after intervals of 1 hour each 
time. The final concentration was determined by weighing the dry residue of a freeze-dried 
aliquot. 
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2.6. Determination of the critical micellar concentration (CMC) 
Nile red was placed in light protected vials (59.5 pmol in each vial) by allowing to evaporate 
an aliquot (11.9 μL) of a 5 μM stock solution in dichloromethane. Several micellar 
dispersions were prepared with concentrations of micelles ranging from 1.5 10-3 to 1.2 mg 
mL-1. For each concentration, micellar dispersion (595 μL) was added to a nile red aliquot to 
reach a final nile red concentration of 0.1 μM in each vial. The mixtures were then stirred 
overnight. Next, nile red fluorescence spectrum was registered from 550 to 700 nm while 
exciting at 560 nm. The relative emission intensity at 606 nm was plotted versus polymer 
concentration and CMC was determined as the concentration corresponding to the intersection 
point of the lower horizontal and the slope tangent. 
2.7. Bedaquiline (BQ) encapsulation 
A typical experiment to determine the optimal amount of BQ for encapsulation started with 
the preparation of a DMSO solution (0.7 mL) containing BQ (0.8-3.0 mg) and ZK30-b-E30 (5 
mg). The solution was stirred for 2 hours to ensure homogeneous mixing and then it was 
added dropwise onto a phosphate buffer solution (pH = 7.4, 10 mM, 4.3 mL) using a syringe 
pump with an addition rate of 0.1 mL min
-1
. Once the addition was completed, the mixture 
was further stirred for 2 hours and then submitted to dialysis against water by replacing it with 
fresh water 5 times after intervals of 1 hour each time. 
The morphology of the micelles was analyzed by Bright Field Transmission Electron 
Microscopy (BF-TEM) in a FEI Tecnai T20 microscope operating at 200 kV. To prepare the 
samples 10 µL of micellar solution were dropped onto a parafilm patch and a TEM grid was 
soaked in the drop. After 30 s, the TEM grid was drawn and the excess solution was removed 
with a filter paper. The TEM grid was then immersed in a drop of phosphotungstic acid. After 
30 s, the excess stain solution was again removed with a filter paper, and the grid was 
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thoroughly washed with water, by three consecutive immersions with fresh milliQ water each 
time. Finally, the sample was allowed to dry overnight. 
Histogram representation of the diameter distribution was obtained using ImageJ software for 
diameter measurement of around 100 particles and OriginLab® (OriginLab, Northampton, 
MA, USA) software to obtain the frequency count statistical analysis. 
2.8. Sodium alginate coated micelles 
Sodium alginate was used to stabilize the micelles. Two different concentrations of sodium 
alginate were used for this purpose, 20 %wt (BQ-M30-L) and 56 %wt (BQ-M30-H), relative 
to the total amount of material. Stabilization with 20 %wt sodium alginate was achieved by 
adding 100 µL of sodium alginate aqueous solution (10 mg mL
-1
) to a BQ-loaded micelles 
(BQ-M30) dispersion (0.8 mg mL
-1
, 5 mL), and stirred 5 minutes to ensure a homogenous 
mixture. Then, the solution was poured into 3 mL of CaCl2 (10 mM) and further stirred for 5 
minutes. The coated particles were washed twice with milli-Q water using centrifugation (6 
min, 4 °C, 16000 rpm). Finally, the content of BQ after coating with sodium alginate was 
evaluated by extracting it from the capsules in DMSO and by spectrophotometric analysis as 
previously described. The same procedure was used for the 56 %wt coating adding 500 µL of 
sodium alginate aqueous solution (10 mg mL
-1
). 
The morphology of alginate-coated micelles was analyzed by Scanning Electron Microscopy 
using a field emission SEM Inspect F50 (FEI). For the measurements of the nanoparticles 
histogram representation of the diameter distribution was obtained using ImageJ software for 
the diameter measurement of around 100 particles and OriginLab® (OriginLab, Northampton, 
MA, USA) software to obtain the frequency count statistical analysis. 
2.9. Determination of bedaquiline (BQ) encapsulation efficiency (EE) and drug 
loading (DL) 
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EE is defined here as the percentage of encapsulated drug over the amount initially added in 
the preparation of nanocarriers. An aliquot of the particle dispersion was withdrawn and 
dissolved in DMSO, in which the carriers are not stable. The concentration of BQ was then 
inferred from its absorbance at 333 nm using a previously obtained calibration curve in 
DMSO. DL is defined as the drug concentration (%wt) in the loaded carrier (BQ-M30, BQ-
M30-L or BQ-M30-H). An aliquot of the micellar solution was withdrawn and then freeze-
dried. The dry residue was weighed, dissolved in DMSO, and the concentration of BQ was 
obtained from the absorbance at 333 nm after interpolation in a calibration curve. 
2.10. Release studies 
All release studies were performed at 37 °C. Human gastric and intestinal simulated media, 
free of enzymes or proteins, were prepared according to published procedures and used for 
drug release experiments.
[23]
 
Briefly, intestinal simulated medium was prepared weighing the corresponding amount of 
salts and diluted in water to reach final concentrations of KCl (0.20 mg mL
-1
), NaCl (8 mg 
mL
-1
), NaH2PO4 (0.24 mg mL
-1
) and Na2HPO4 (0.24 mg mL
-1
). Finally, pH was adjusted to 
pH 7. 
Enzyme-free gastric simulated media consisted in a 2 mg mL-1 NaCl solution adjusted to pH 
1.6. 
Also 0.9 % NaCl and water (storage medium) were used for the experiments. BQ-loaded 
nanocarriers were mixed with the appropriate medium at a concentration of 0.1 mg mL-1 BQ-
loaded nanocarrier and incubated at 37 °C with gentle agitation. With these conditions, 
bedaquiline total concentration was below 20 μg mL-1 and sink conditions were likely met.[24] 
Samples were analyzed immediately after mixing (t = 0) and after 2, 4 and 24 h at 37 °C. For 
the analysis, the dispersion was passed through a nylon syringe filter (0.45 μm pores) to 
separate the carrier (retained in the filter) from the medium. Then, 500 μL of DMSO were 
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passed through the filter to extract BQ still encapsulated. The concentration of BQ in DMSO 
was measured by spectrophotometric analysis of the absorbance at 333 nm and the amount of 
released drug was obtained by difference with the drug loading. Despite their small size, 
polypeptidic micelles were retained in the nylon syringe filters, which are known to show 
high protein adhesion. For validation, dispersions of empty polypeptidic micelles (M30) at 
different concentrations (0.1-1.0 mg mL-1) were filtered and the filtrate was analyzed using 
Bradford colorimetric assay and fluorescamine assay methods. In all cases, if present, 
polypeptide was in a concentration below our limit of detection (< 0.05 mg mL-1). 
Release experiments in human plasma were performed with a more diluted concentration 
(0.05 mg mL-1 BQ-loaded nanocarrier) to prevent precipitation. The samples were incubated 
at 37 °C with gentle agitation. Time points were registered in the same manner as in other 
media but employing methanol as organic solvent. After filtration, the organic solution was 
centrifuged 10 min 14000 rpm and the supernatant was submitted to UV-Vis spectroscopy for 
bedaquiline quantification. 
All release experiments were done in triplicate. 
2.11. Bacterial strains and culture conditions 
The Mycobacterium tuberculosis reference strain H37Rv,[25] available at Mycobacterial 
Genetics Group Laboratory (University of Zaragoza), was routinely grown in Middlebrook 
7H9 medium supplemented with 10% ADC and 0.05% Tween® 80 at 37ºC within a BLS 3 
laboratory. 
2.12. In vitro antimicrobial activity assay 
The Minimum Inhibitory Concentration (MIC) was determined using the method of Resazurin 
Microtiter Assay Plate (REMA).[26] In 96-well plates, a range of concentrations of the free 
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bedaquiline or bedaquiline-loaded nanoparticles were added in 100 µL of Middlebrook 7H9 
medium supplemented with 10 % ADC and 0.5 % glycerol, in a series of two-fold dilutions 
spanning from 1 to 0.008 µg mL-1. Empty nanoparticles were assayed as a control. Bacteria 
were inoculated by adding 100 µl of a suspension of 105 CFU mL-1, as estimated by optical 
density and prepared from a culture in exponential growth phase. After 6 days of incubation at 
37 °C, 30 µL of resazurin (0.01 % w/v) was added to each well, further incubated for 48 h at 
37 °C, and assessed for color change. A change of the suspension from blue to pink indicates 
the reduction of resazurin to resorufin corresponding to bacterial growth. The MIC was 
defined as the lowest drug concentration that prevented the bacterial growth as indicated by 
resazurin color change. 
 
3. Results and Discussion 
3.1. Synthesis of the amphiphilic polymers 
Polypeptides can be synthesized through ring opening polymerization (ROP) with the N-
carboxyanhydride (NCA) of the corresponding aminoacids. The synthesis of the NCAs 
requires that the functional groups in the side chain of the aminoacids are protected. 
Therefore, we followed reported procedures for the synthesis of γ-benzyl-L-glutamic acid 
NCA (BnE-NCA) and ϵ-N-benzyloxycarbonyl-L-lysine NCA (ZK-NCA) as monomers for 
the ROP, as these protecting groups would allow for the selective deprotection of the 
polyglutamate block after ROP to achieve the targeted amphiphilic polymers (Scheme 1). 
Provided the sensitivity of polymerization reactions to the purity of the monomers we paid 
special attention to this parameter and recrystallized 5 times each monomer prior to ROP 
reactions. 
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Scheme 1. Synthesis of ZK30-b-BnEn polypeptides. 
 
The synthesis of block copolymers with controlled degree of polymerization of each block 
requires working in living polymerization conditions, that is, chain termination and chain 
transfer reactions do not take place and the rate of initiation reaction is much faster than the 
rate of propagation. Under living polymerization conditions, block copolymers can be 
synthesized through the consecutive addition of monomers: first, one monomer is added to the 
initiator for polymerization and when the reaction mixture is depleted of monomer the 
polymer chains can be used as macroinitiators for the polymerization of the second monomer. 
ROP of NCAs can be run under living polymerization conditions using a variety of initiators 
including transition metal complexes, thiols, silazanes, amines and ammonium salts with 
tetrafluroborate or chloride anions. Most often, the ROP needs to be run under high vacuum 
and/or low temperature to optimize the conditions needed for a living polymerization for 
block copolymers or high molecular weight polymers.[27] Based on the reports we tested the 
ROP of BnE NCA initiated by butyl amine under vacuum conditions at room temperature and 
evaluated the polymerization based on gel permeation chromatography, 1H NMR and MALDI 
ToF mass spectrometry of the obtained polymers. MALDI spectra showed peaks due to 
chains grown by the desired normal amine mechanism (NAM), which is initiated by the 
amine, and peaks due to competitive activated monomer mechanism (AMM), in which the 
amine deprotonates the –NH– of one NCA monomer which then acts as initiator (Figure S9). 
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Lowering the temperature of the reaction to 0 ºC, decreased the relative intensity of the AMM 
peaks but the increased reaction times led to the appearance of a peak series due to 
formylation, which is a termination reaction due to the solvent. In view of the results, we 
tested the same reaction conducted under a continuous flow of nitrogen gas as reported by 
Zou et al.[22] The flow of nitrogen gas allows the removal of carbon dioxide released during 
ROP which results in an increase of the overall reaction rate. With these conditions 
formylation of the growing polymeric chains was prevented and peaks due to AMM were 
minimized (Figure S9). 
We then applied those conditions to the sequential block copolymerization of ZK NCA and 
BnE NCA to obtain the targeted block copolymers as shown in Scheme 1. We used 1H NMR, 
and GPC as main tools for the characterization of the ZK30-b-BnEn polypeptides in terms of 
degree of polymerization, ratio between blocks and polydispersity (Table 1). 
 
Table 1. Characterization data of the prepared block copolymers. 
Polymera) Mn,expected 
[×10-4 Da] 
Mn,NMR
b)
 
[×10-4 Da] 
RatioNMR
b) Mn,GPC
c)
 
[×10-4 Da] 
PDIc) Yield 
[%] 
ZK30-b-BnE30 1.45 1.76 1:37:36 1.97 1.17 > 99 
ZK30-b-BnE60 2.11 2.06 1:30:50 2.62 1.16 97 
 
a) The polymerization reactions were carried out with a flow of N2 in DMF at 25 °C with [n-
Bu-NH2]o = 0.025 M [ZK NCA]o = 0.76 M. 
b) 1H NMR spectroscopy. c) GPC-MALS, 0.1 M 
LiBr in DMAc at 60 °C. 
 
As expected, the ratio between both blocks was essentially preserved as shown by 1H NMR 
spectroscopy (Figure 1), only slightly shifted compared with the theoretical one based on the 
feed. GPC analyses yielded monomodal molecular weight distributions with a remarkable 
reproducibility among batches as verified by GPC trace analysis (Figure 1).[28] 
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Figure 1. A) 1H NMR spectrum of ZK30-b-BnE30 in DMSO-d
6 and integrals used for the 
calculation of Mn,NMR and the ratio between blocks from Table 1. B) GPC profiles (Rayleigh 
ratio signals) of copolymerization of BnE NCA and ZK NCA with different DP: black 
(30:30) Mn,GPC = 1.97 × 10
4 Da, PDI = 1.17; red (30:60) Mn,GPC = 2.62 × 10
4 Da, PDI = 1.16; 
blue (30:60) Mn,GPC = 2.64 × 10
4 Da, PDI = 1.14. 
 
The amphiphilic structures were obtained by deprotection of the benzyl ester moieties by 
basic hydrolysis using KOH in THF
[16]
 with subsequent purification by dialysis. This 
purification step enabled us to perfectly remove the reagents and the organic solvent and was 
suitable for both polymer lengths. The amphiphilic structures were characterized by 
1
H NMR, 
yet just the hydrophilic signals were detected in deuterium oxide, due to the lack of solubility 
of the hydrophobic part (Figure S8). Other basic conditions for the deprotection step afforded 
similar results based on yield and purity.
[29]
 
3.2. Self-assembly behavior of the amphiphilic polymers 
ZK30-b-E60 and ZK30-b-E30 are amphiphilic block copolymers designed to self-assemble in 
aqueous solution so that the contact of the hydrophobic block, ZK30, with the aqueous 
environment is minimized. The morphology of the self-assembled structures primarily 
depends on the nature of the blocks, on the total length and on the internal structure of the 
block copolymer, meaning by this the number and relative lengths of the blocks. Taking into 
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account those parameters and previous reports, we expected to obtain micelles from the 
synthesized amphiphilic copolymers.
[16]
 
Based on the solubility of ZK30-b-E60 and ZK30-b-E30 we selected the nanoprecipitation 
method as the most suitable for the formation of self-assembled structures (Figure S10). It 
consists of dissolving the block copolymer in an organic solvent in which both blocks are 
soluble thereupon adding an aqueous solution in which one of the blocks is not soluble. 
During this process, water diffuses into the organic phase, leading to the aggregation of the 
hydrophobic chains and the self-assembly of the amphiphilic block copolymers. Finally, the 
organic solvent can be removed by evaporation or dialysis. 
In our studies on the self-assembly of ZK30-b-E60 and ZK30-b-E30 we used DMSO as organic 
solvent as the polymers were more readily solubilized in it than in THF and insoluble in other 
organic solvents. A phosphate buffer was selected as non-solvent for the hydrophobic block. 
Once the addition of the aqueous solution was completed, DMSO was removed by dialysis 
(Figure S10). 
This method allowed the formation of micelles in a reproducible manner with both polymers. 
Dynamic light scattering (DLS) was used to measure the hydrodynamic diameter of the 
obtained micelles (Table 2), which were found to be larger for ZK30-b-E60 than for ZK30-b-
E30. The hydrodynamic diameter between 70 and 90 nm of the micelles M30 obtained from 
ZK30-b-E30 was consistent with other reported micelles from polypeptides with similar degree 
of polymerization.
[12] 
However the M60 produced from ZK30-b-E60 were larger than expected 
from the difference in the polymer length. 
ζ-potential value was found negative for both preparations, as expected from the hydrophilic 
block consisting of a polycarboxylic acid under measuring conditions, well above its pKa. 
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Table 2. Characterization results for the carriers formed by ZK30-b-Em. 
Micelle Polymer DH
a)
 
[nm] 
PDIb) CMCc)  
[mg mL-1] 
ζ-potential 
[mV] 
M30 ZK30-b-E30 80.0  8.0 0.12  0.05 0.03 -36.8  2.2 
M60 ZK30-b-E60 194.3  7.1 0.13  0.01 0.18  -50.6  2.6 
 
a) Hydrodynamic diameter as determined by dynamic light scattering (DLS). b) Polydispersity 
index. c) Critical micellar concentration. 
 
Finally, the stability of micelles against dilution was assessed by measuring the critical 
micellar concentration through the encapsulation of nile red dye at different dilutions. The 
lower value obtained for ZK30-b-E30 indicated that its aggregates would be stable in a broader 
concentration range than M60 which is key for their application in drug delivery (Table 2 and 
Figure S11). 
Provided the higher stability toward dilution of M30 aggregates compared to M60, we 
decided to focus our encapsulation studies on M30. 
3.3. Encapsulation of bedaquiline (BQ) 
BQ is an effective antimicrobial drug which is indicated for the treatment of MDR–TB.[19] 
Unfortunately, treatment with BQ is expensive
[30]
 and has also been associated to important 
side effects, which makes advisable the use of alternative drug delivery strategies, so that 
bioavailability could be increased and dosing reduced.
[17,20] 
Taking advantage of the 
hydrophobic nature of BQ, its encapsulation in a drug carrier is the strategy of choice as any 
chemical modification of the drug is avoided and its solubility and bioavailability might be 
enhanced.  
Due to the scarce solubility of BQ in water, for its encapsulation we first applied our method 
of preparation of M30 (Figure S10), in which BQ could be introduced after dissolving it in 
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DMSO with the polymer. However, adding the buffer dropwise into a BQ and polymer 
solution in DMSO led to precipitation of BQ. In consequence, we decided to modify the 
method by adding the solution in DMSO into the phosphate buffer (Figure S12). Different 
initial BQ/ZK30-b-E30 mass ratios (R) between 0.15 and 0.60 (Table S1) were tested to obtain 
BQ-loaded micelles. The encapsulation efficiency increased with R until it reached a 
maximum of 60 % for R = 0.30. However, at that ratio BQ partially precipitated, making 
difficult the purification of the loaded micelles. For higher values of R the encapsulation 
efficiency (EE) decreased as precipitation increased and the loaded micelles became less 
stable. Therefore, a ratio R = 0.24 was selected as optimal considering the stability of the 
resulting loaded micelles, BQ-M30, as well as the obtained encapsulation efficiency (58.3  
10.0 %) and drug loading (19.2  3.0 %) (Table 3). With that ratio between the BQ and the 
polymer in the feed (R = 0.24) we prepared all the batches used in this work in scales in the 
range 50-100 mg of starting polymer. 
 
Table 3. Characterization results for bedaquiline loaded carriers. 
Carriera) DH
b)
 
[nm] 
PDI Diameter 
[nm] 
ζ-potential 
[mV] 
DLc) 
[%] 
EE 
[%] 
BQ-M30 47.5  3.1 0.125 
 0.04 
18.2  3.5d -23.6  1.8 19.2  
3.0 
58.3  
10.0 
BQ-M30-L 435.8  
17.0 
0.245 
 0.03 
228.6  30.4e -25.2  2.2 17.3  
0.6 
NA 
BQ-M30-H 406.0  
28.3 
0.238 
 0.01 
243.6  34.5e -28.0  1.3 16.5  
2.1 
NA 
 
a) BQ-M30: bedaquiline-loaded polypeptidic micelles. BQ-M30-L: bedaquiline-loaded 
polypeptidic micelles coated with alginate (20 %wt). BQ-M30-H: bedaquiline-loaded 
polypeptidic micelles coated with alginate (56 %wt). b) The hydrodynamic diameter (DH) was 
obtained from DLS measurements. c) Drug loading is the concentration (%wt) of bedaquiline 
in the loaded carrier (BQ-M30, BQ-M30-L or BQ-M30-H). d) The diameter of the particles 
was measured in TEM images. e) The diameter of the particles was measured in SEM images. 
 
In literature, bedaquiline encapsulation and vehiculization has been reported only very 
recently with nanoemulsion-based nanocarriers 
[31]
 and polymeric nanoparticles.
[24] 
Our work 
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is the first successful attempt to encapsulate bedaquiline in polymeric micelles. DL and EE 
percentages obtained in our work are quite comparable with those obtained with chitosan 
coated nanoparticles (i.e. 28 % DL and 70 % EE) and herein reported DL of bedaquiline in 
polymeric micelles is much higher than the one obtained with lipid nanoparticles (i.e. 2.8 
%).[31] 
3.4. Stabilization of the micelles with alginate 
Polymeric micelles have been extensively used for drug delivery purposes and now there is 
increasing evidence that they need to be stabilized to prevent premature disintegration and to 
improve their performance.[10] Covalent crosslinking of the core of the micelle is the approach 
followed most often for such stabilization, which involves a higher synthetic complexity. 
Herein we propose a supramolecular coating with sodium alginate, a naturally occurring 
polysaccharide, which is already approved by FDA along with calcium alginate and alginic 
acid. Sodium alginate is known to form hydrogels upon addition of CaCl2. Our hypothesis 
was that the interaction between the polysaccharide and the polyglutamic segments through 
coordination of calcium ions could stabilize the micelles surface. Thus, loaded particles were 
coated through ionotropic gelation process, by the consecutive treatment of the micelles with 
sodium alginate and CaCl2 to afford the desired nanogel coating (Figure 2). 
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Figure 2. Block copolypeptide for the encapsulation of bedaquiline in the hydrophobic core of 
the micelle. Following drug encapsulation, the micelles are coated with alginate for 
stabilization. 
 
Different sodium alginate quantities were tested to stabilize the micellar formulation, a lower 
amount of 20 %wt (BQ-M30-L) and a higher amount of 56 %wt (BQ-M30-H), so that its 
effect in the structure of the assembly and on the final properties for release could be assessed. 
Both alginate amounts provided stable colloidal solutions. Interestingly, the pellets formed by 
BQ-M30-L and BQ-M30-H upon centrifugation could be readily redispersed, which 
facilitated the purification of the particles. Non-stabilized micelles M30 and BQ-M30, on the 
contrary, did not afford a pellet after centrifugation and had forced us to use dialysis for 
purification.  
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3.5. Nanocarriers characterization 
Bedaquiline-loaded micelles before and after stabilization with alginate were submitted to 
physicochemical characterization to determine their physical characteristics (mainly size and 
surface potential). 
The comparison between the hydrodynamic diameter distribution of BQ-loaded micelles 
before and after their stabilization with sodium alginate is reported in Figure 3 and Table 3. 
 
 
Figure 3. DLS data for the BQ-loaded nanocarriers: BQ-M30 (A), BQ-M30-L (B) and BQ-
M30-H (C). 
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The structural characterization of the loaded micelles, BQ-M30, indicated that BQ could act 
as a scaffold that triggers the formation of the micelle around it.[16] Indeed, loaded micelles 
were around 50 nm diameter by DLS, smaller than the non-loaded ones which were about 80 
nm. This shift can be attributed to the hydrophobic forces that improved the stacking of ZK 
chains around the aromatic drug (Figure 3A).[8,16] 
The particles observed after stabilization with alginate were much larger according to DLS 
measurements, with a hydrodynamic diameter around 300-500 nm for both alginate 
concentrations. ζ -potential of the capsules remained negative as expected from the presence 
of negatively charged carboxylate groups in the alginate coating. 
BQ-M30 could be imaged using BF-TEM (Figure 4A and B), which revealed a particle size 
around 20 nm (Figure 4C), consistent with the DLS measurements (Table 3). BQ-M30-H and 
BQ-M30-L could be studied by SEM (Figure 4D and E and Figure S13). In both cases also 
the frequency analysis of the size distribution is reported (Figure 4F and Figure S13C). 
 
 
 
Figure 4. BF-TEM micrographs of bedaquiline loaded micelles BQ-M30 (A and B) and 
histogram of the preparation (C). SEM micrographs of bedaquiline-loaded alginate coated 
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particles using 56 % wt alginate BQ-M30-H (D and E). Histogram obtained from SEM 
images of BQ-M30-H (F). 
 
BQ-M30-H and BQ-M30-L appeared as spheres with diameters between 200 and 300 nm 
significantly larger than the starting BQ-loaded micelles BQ-M30. It is remarkable that the 
size of the carriers seemed to be independent of the amount of alginate we added. The higher 
amount of alginate could contribute to a denser rather than thicker coating or could just be 
eliminated in the purification. The results were consistent with the DLS estimations of the 
hydrodynamic diameter if we take into account that the polymeric particles are likely to 
contract in the measuring conditions. The size and the morphology of the isolated particles 
were consistent among different sample preparations.  
3.6. Drug release in controlled media 
The potential of the nanocarriers for BQ administration was assessed by measuring the profile 
of the release of bedaquiline from nanocarriers at 37 °C under conditions relevant to 
intravenous and oral administration. 
To explore the behavior of our nanocarriers for intravenous administration, we first evaluated 
the effect of dilution for each carrier in water and in a NaCl solution in water (0.9 %wt) 
respectively as storage and vehicle media for that administration route (Figure 5A).  
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Figure 5. A) Released bedaquiline immediately after 1:10 dilution of the loaded carriers in 
water and in NaCl (0.9 %wt). B) Release profile in human plasma at 37 ºC of the bedaquiline 
encapsulated in micelles coated with alginate at the highest content, BQ-M30-H. 
In intravenous administration the formulation would be injected short or immediately after 
dilution in the administration medium. Thus, we measured the bedaquiline released from the 
nanocarriers immediately after a ten-fold dilution in each medium, from 1.0-3.0 mg mL-1 to 
0.1-0.3 mg mL-1 in polymer concentration, depending on the batch. That concentration is 
close to the measured CMC of the polymer, 0.03 mg mL-1 (Table 2). In these conditions BQ-
M30 showed a burst release of 26 % and 30 % respectively in water and NaCl solution, which 
was consequence of the instability of the micelles upon dilution, even though the final 
concentration was still above the CMC (Table 2). As expected, coating the micelles with 
alginate provided the desired effect and notably reduced the amount of released BQ below 5 
% for both BQ-M30-H and BQ-M30-L (Figure 5A). When comparing the alginate coated 
micelles at the two percentages of polysaccharide, we expected lower values for BQ-M30-H 
compared to BQ-M30-L if we consider the denser alginate shell that could be hypothesized 
for BQ-M30-H. Indeed, BQ-M30-H provided a lower BQ release upon dilution, below 2 % 
in either media, although the difference with BQ-M30-L fell within the error limits. 
Blood and plasma are very complex media in which the large amount of proteins and 
biomolecules present could adsorb to any injected nanoparticle. Interactions are mostly 
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hydrophobic or ionic and will probably accelerate the release of an encapsulated drug or, in 
the case of micelles, seriously compromise the integrity of the carrier.[32] From the presented 
carriers, BQ-M30-H was expected to be the most stable in protein-containing media because 
the larger amount of alginate would assure that no bare micelles are present in the sample. 
Thus, we performed a series of experiments to obtain the release profile in plasma of the BQ 
encapsulated in BQ-M30-H (Figure 5B). The amount of BQ initially released was remarkably 
low (14.3 % ± 3.8) taking into account the complexity of the medium. Following that, we 
observed a sustained release of BQ reaching 58.0 % ± 1.4 after 24 h. This result indicates BQ-
M30-H can be a very good candidate for intravenous administration to extend the circulation 
time of BQ and increase its probability to reach infected cells. 
Sodium alginate is known also for its mucoadhesive properties that make it a very good 
candidate for the development of drug delivery systems for gastrointestinal applications.[15] To 
evaluate the future possibility to use these nanocarriers for oral administration, we selected 
gastric simulated (GS) medium and intestinal simulated (IS) medium (both of them enzyme-
free) to study the stability of the drug loading and the corresponding release profiles of the 
encapsulated BQ in these media (Figure 6). 
 
 
 
Figure 6. Release profile at 37 °C of bedaquiline encapsulated in micelles before and after 
alginate coating in A) human gastric simulated medium and B) intestinal simulated medium. 
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We planned the experiments on a 4 h long basis taking into account that upon oral 
administration the carrier is expected to leave the stomach and enter in contact with intestinal 
environment (small bowel) during this period of time.[33] It is desired that in either medium the 
amount of released BQ is minimal so that the loaded carriers can be retained integer in the 
intestine for a sustained release of the encapsulated drug and its absorption. 
The main feature of the GS medium is the strongly acidic pH. BQ-M30 exhibited a strong 
initial burst release similar in magnitude to that previously observed in water. BQ-M30 
partially aggregated for the next data points (Figure 6) and we had a high dispersion in our 
results. The pH of GS medium was well below the pKa of the carboxylic acids of the outer 
polyglutamate block, which led to aggregation of the micelles after their outer part became 
hydrophobic due to protonation of the carboxylic groups. Alginate coated carriers exhibited 
better stability as shown by the much lower amount of released BQ and also by the lower 
standard deviation of the repetitions. Even though the carboxylate groups of alginate probably 
became protonated, the carriers remained soluble in the medium due to the polar 
polysaccharide chains. 
Intestinal simulated medium was mainly characterized by a neutral pH and the presence of 
phosphate ions. The stability of the alginate coated carriers in this medium could have been 
compromised due to the phosphate ions in the medium sequestering the Ca2+ cations that keep 
the carrier pieces together to form insoluble calcium phosphate. However, to our satisfaction 
BQ-M30-H and BQ-M30-L showed a good performance with less than 25 % of released BQ 
in this medium after 4 h, a promising behavior for possible future study of oral administration 
in animal models. 
 
3.7. In vitro antimicrobial activity 
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We used the well-established REMA assay,[26] to determine the in vitro antimicrobial activity 
of the encapsulated BQ against M. tuberculosis H37Rv and then we compared the minimum 
inhibitory concentration (MIC) obtained to that of free bedaquiline (Table 4). The MIC of 
empty carriers was studied as well, to ensure that within the range of concentrations used in 
the assay, the antibacterial effect was only due to the antimicrobial drug and not to the 
nanocarrier itself. The MIC for the empty carrier was found to be above 250 µg mL-1 in all 
cases. As shown in Table 4, not only bedaquiline was still very active against M. tuberculosis 
after encapsulation in any of the carriers but the activity seems to be increased 2 times. These 
results were reproduced using different batches of capsules. 
 
Table 4. MIC values for free and encapsulated bedaquiline. All experiments were done in 
triplicate. 
Sample 
MIC of bedaquiline free or 
encapsulated 
[µg mL-1] 
Corresponding concentration of 
nanocarrier 
[µg mL-1] 
BQ (free drug) 0.03 - 0.06 - 
BQ-M30 0.015 – 0.03 0.08 – 0.17 
BQ-M30-L 0.015 – 0.03 0.09 – 0.18 
BQ-M30-H 0.015 – 0.03 0.09 – 0.19 
 
At the concentrations used in the assay, the empty carriers do not show any antibacterial 
activity. However, it seems to enhance the activity of bedaquiline. This could be due to an 
increase in the solubility of bedaquiline and consequent higher bioavailability. But another 
hypothesis even more interesting is that the mucoadhesive nature of the polymer and the 
alginate could provide the particles with the ability to get stuck to bacterial surface, hence 
delivering more efficiently BQ closer to its target. 
Provided that other carriers enhancing the solubility of BQ did not lead to an increased 
activity of the encapsulated BQ,[31] we are currently planning future experiments to elucidate 
the origin of this increased activity. 
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4. Conclusions 
In this work we have shown that a coating with sodium alginate is a good strategy to stabilize 
polypeptidic micelles and improve their properties regarding release profiles. This strategy 
does not affect the core of the carrier or the loaded drug and might be compatible with more 
complex polymer structures for controlled drug detachment. The synthesis of the micelles has 
been tested to a 100 mg scale without any particular adaptation. 
Taking altogether, our results on the release of encapsulated BQ from the alginate-coated 
polypeptidic micelles show alginate coating is a promising strategy to overcome the 
limitations of polymeric micelles in terms of stability. Coating the micelles with sodium 
alginate preserved the properties of the micelles for encapsulation while notably reducing the 
initial burst release in all tested media. Chosen media were relevant for oral and intravenous 
administration. In particular, BQ-M30-H showed a 15-fold decrease of released BQ 
compared to micelles BQ-M30 and, furthermore, a sustained release in a complex medium 
such as human plasma. Release of BQ from alginate-coated carriers was also reduced in 
gastric and intestinal simulated media to values well below 25 %. This means that, thanks to 
sodium alginate mucoadhesive properties, BQ would be probably slowly released from the 
nanocarrier and well absorbed in the intestine. In this way, the treatment can benefit from the 
advantages of the use of a nanotechnology based drug delivery system. 
Remarkably the formulations of encapsulated bedaquiline showed a lower MIC compared to 
free BQ. This interesting result open the way for further investigations on the role of this 
specific nanocarrier on drug delivery and antimicrobial action.  
To conclude, our approach allows the utilization of easily accessible polypeptides for 
encapsulation and scaling of the self-assembly process. In the near future, we plan to elucidate 
the causes for the improved activity of the released BQ in the presence of the polypeptide and 
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we also plan to adapt the synthetic process to other polysaccharides suitable for other routes 
of administration.  
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Supporting Information 
Supporting Information is available from the Wiley Online Library or from the author. 
The following files are available free of charge: brief description (PDF): The methods of 
synthesis and the characterization of the monomers and the polymers by NMR measurements 
are provided in the supporting information. The methods for the preparation of the micelles 
and bedaquiline micelles are also described in the supporting information along with data of 
the optimization of the amount of bedaquiline for encapsulation and SEM images for BQ-
M30-L. 
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Bedaquiline shows higher activity against Micobacterium Tuberculosis after 
encapsulation in polypeptidic micelles. The micelles are obtained from an amphiphilic 
block polypeptide and coated with an alginate gel for stabilization. It is shown that this is a 
good strategy to stabilize polypeptidic micelles and improve their properties regarding release 
profiles. 
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